| Literature DB >> 28125071 |
Attila Hunyadi1,2, József Csábi3, Ana Martins4, Joseph Molnár5, Attila Balázs6, Gábor Tóth7.
Abstract
P-glycoprotein (P-gp, ABCB1) over-expression, causing a multi-drug resistant (MDR) phenotype, is a major problem in cancer chemotherapy that urgently requires novel approaches. Our previous studies showed certain ecdysteroid derivatives as promising chemo-sensitizers against MDR and non-MDR cancer cell lines while also exerting mild to moderate inhibition of P-gp function. Here we report the preparation of a set of substituted 2,3-dioxolane derivatives of poststerone, a known in vivo metabolite of 20-hydroxyecdysone (20E). In contrast with previously studied ecdysteroid dioxolanes, the majority of the new compounds did not inhibit the efflux function of P-gp. Nevertheless, a strong, dose dependent sensitization to doxorubicin was observed on a P-gp transfected cancer cell line and on its susceptible counterpart. We also observed that the MDR cell line was more sensitive to the compounds' effect than the non-MDR. Our results showed for the first time that the chemo-sensitizing activity of ecdysteroids can be fully independent of functional efflux pump inhibition, and suggest these compounds as favorable leads against MDR cancer.Entities:
Keywords: ABCB1 efflux transporter; cancer; chemo-sensitization; combination therapy; ecdysteroid metabolite; multi-drug resistance; poststerone acetonide
Mesh:
Substances:
Year: 2017 PMID: 28125071 PMCID: PMC6155823 DOI: 10.3390/molecules22020199
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Chemical structures of compounds 1–10.
1H-NMR chemical shifts of compounds 1–10, in ppm, in MeOH-d4.
| Atom No. | 1 | 2 a | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 a |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 β | 1.44 | 1.24 | 1.18 | 1.17 | 1.44 | 1.18 | 1.23 | 1.26 | 1.23 | 1.25 |
| α | 1.80 | 2.01 | 2.00 | 1.94 | 2.01 | 1.98 | 2.00 | 1.99 | ||
| 2 | 3.86 | 4.28 | 4.23 | 4.23 | 4.00 | 4.22 | 4.27 | 4.29 | 4.29 | 4.29 |
| 3 | 3.97 | 4.31 | 4.13 | 4.13 | 5.17 | 4.13 | 4.31 | 4.27 | 4.34 | 4.32 |
| 4 β | 1.74 | 2.02 | 2.02 | 1.78 | 2.02 | 1.98 | 1.98 | 1.99 | ||
| α | 1.74 | 2.02 | 2.02 | 1.78 | 2.02 | 1.98 | 1.98 | 1.99 | ||
| 5 | 2.39 | 2.25 | 2.25 | 2.22 | 2.25 | 2.23 | 2.25 | 2.24 | ||
| 7 | 5.82 | 5.80 | 5.81 | 5.80 | 5.83 | 5.80 | 5.80 | 5.80 | 5.80 | 5.80 |
| 9 | 3.19 | 2.98 | 2.99 | 2.99 | 3.21 | 2.99 | 2.97 | 2.97 | 2.97 | 2.96 |
| 11 β | 1.67 | 1.67 | 1.67 | 1.69 | 1.66 | 1.66 | 1.66 | 1.65 | ||
| α | 1.89 | 1.88 | 1.88 | 1.89 | 1.87 | 1.87 | 1.86 | 1.86 | ||
| 12 β | 1.82 | 1.81 | 1.81 | 1.83 | 1.81 | 1.80 | 1.81 | 1.81 | ||
| α | 2.33 | 2.32 | 2.32 | 2.32 | 2.35 | 2.32 | 2.32 | 2.32 | 2.32 | 2.32 |
| 15 β | 2.00 | 2.00 | 2.02 | 2.01 | 2.01 | 1.99 | 2.00 | 2.00 | ||
| α | 1.70 | 1.69 | 1.69 | 1.69 | 1.69 | 1.69 | 1.68 | 1.68 | ||
| 16 β | 2.23 | 2.25 | 2.26 | 2.26 | 2.25 | 2.24 | 2.25 | 2.25 | ||
| α | 1.88 | 1.88 | 1.90 | 1.89 | 1.89 | 1.88 | 1.89 | 1.88 | ||
| 17 | 3.33 | 3.32 | 3.32 | 3.32 | 3.33 | 3.33 | 3.33 | 3.34 | 3.32 | 3.32 |
| 18 | 0.62 | 0.62 | 0.62 | 0.62 | 0.63 | 0.62 | 0.61 | 0.62 | 0.61 | 0.61 |
| 19 | 0.96 | 0.96 | 0.96 | 0.96 | 0.99 | 0.96 | 0.96 | 0.97 | 0.95 | 0.96 |
| 21 | 2.16 | 2.15 | 2.15 | 2.15 | 2.16 | 2.15 | 2.15 | 2.15 | 2.15 | 2.15 |
| R1 | - | 1.47 | 0.98 | 0.97 | 0.99 | 0.93 | 0.98 | 1.42 | 0.90 | 0.95 |
| R2 | - | 1.32 | 4.90 | 4.95 | - | 4.94 | 1.30 | 0.92 | 1.28 | 0.88 |
a Only the characteristic 1H chemical shifts were assigned for compounds 2 and 10, considering that these compounds contain identical R1 and R2 groups, hence diastereomer pairs at C-22 were not distinguishable.
13C-NMR chemical shifts of compounds 1–10, in ppm, in MeOH-d.
| Atom No. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 37.4 | 38.8 | 39.5 | 39.5 | 38.5 | 39.6 | 39.0 | 39.0 | 38.94 | 39.1 |
| 2 | 68.7 | 73.6 | 72.9 | 72.8 | 67.2 | 72.8 | 73.2 | 73.2 | 73.2 | 72.8 |
| 3 | 68.5 | 73.2 | 75.0 | 75.0 | 71.6 | 75.0 | 72.6 | 73.6 | 72.8 | 73.2 |
| 4 | 32.9 | 27.8 | 27.8 | 27.8 | 30.5 | 27.8 | 27.8 | 27.8 | 27.8 | 27.8 |
| 5 | 51.9 | 52.6 | 52.6 | 52.6 | 52.8 | 52.6 | 52.8 | 52.6 | 52.6 | 52.6 |
| 6 | 206.3 | 205.5 | 205.3 | 205.3 | 205.2 | 205.3 | 205.5 | 205.4 | 205.5 | 205.4 |
| 7 | 122.6 | 122.3 | 122.4 | 122.3 | 122.5 | 122.3 | 122.3 | 122.3 | 122.3 | 122.3 |
| 8 | 166.6 | 165.9 | 166.0 | 166.0 | 166.8 | 166.0 | 166.0 | 165.9 | 165.9 | 165.9 |
| 9 | 35.2 | 35.9 | 36.3 | 36.3 | 35.4 | 36.3 | 36.1 | 36.0 | 36.0 | 36.0 |
| 10 | 39.3 | 39.0 | 38.8 | 38.7 | 39.3 | 38.8 | 38.9 | 38.9 | 38.9 | 38.9 |
| 11 | 21.7 | 21.8 | 21.9 | 21.9 | 21.7 | 21.9 | 21.8 | 21.8 | 21.8 | 21.8 |
| 12 | 31.1 | 31.2 | 31.2 | 31.2 | 31.2 | 31.2 | 31.2 | 31.2 | 31.2 | 31.2 |
| 13 | 48.9 | 49.1 | 49.2 | 49.2 | 48.8 | 49.1 | 49.4 | 49.2 | 49.2 | 49.0 |
| 14 | 85.1 | 85.0 | 85.0 | 85.0 | 85.1 | 85.0 | 85.1 | 85.0 | 85.0 | 85.0 |
| 15 | 32.2 | 32.1 | 32.1 | 32.1 | 32.2 | 32.1 | 32.1 | 32.1 | 32.1 | 32.1 |
| 16 | 22.3 | 22.3 | 22.3 | 22.3 | 22.3 | 22.3 | 22.3 | 22.3 | 22.3 | 22.3 |
| 17 | 60.2 | 60.2 | 60.2 | 60.2 | 60.2 | 60.2 | 60.2 | 60.2 | 60.2 | 60.2 |
| 18 | 17.6 | 17.6 | 17.6 | 17.6 | 17.6 | 17.6 | 17.6 | 17.6 | 17.6 | 17.6 |
| 19 | 24.5 | 24.1 | 24.1 | 24.1 | 24.5 | 24.1 | 24.2 | 24.1 | 24.1 | 24.2 |
| 20 | 212.6 | 212.6 | 212.5 | 212.5 | 212.5 | 212.5 | 212.5 | 212.5 | 212.5 | 212.5 |
| 21 | 31.6 | 31.6 | 31.6 | 31.6 | 31.6 | 31.6 | 31.6 | 31.6 | 31.6 | 31.6 |
| 22 | - | 109.6 | 106.7 | 105.7 | 175.1 | 105.9 | 111.4 | 111.7 | 111.5 | 113.5 |
| R1 | - | 28.9 | 8.80 | 14.5 | 14.1 | 14.4 | 24.9 | 25.7 | 9.5 | 9.07 |
| R2 | - | 26.7 | - | - | - | - | 24.4 | 9.40 | 23.6 | 9.11 |
Figure 2Stereostructure and one-dimensional selective Rotating frame Overhauser Enhancement Spectroscopy (ROESY) responses (irradiated at R2: δ = 1.28 ppm) of compound 8. Blue numbers refer to 1H chemical shifts; black numbers give the 13C δ values.
Functional inhibition of P-gp by compounds 1–10. a
| Compound | Inhibition (%) | Compound | Inhibition (%) | ||
|---|---|---|---|---|---|
| 2 μM | 20 μM | 2 μM | 20 μM | ||
| 0.31 | 0.43 | −0.06 | 2.32 | ||
| 0.08 | 0.64 | 3.08 | 56.36 | ||
| 0.24 | 0.29 | −0.19 | 0.19 | ||
| 0.03 | 3.85 | −0.32 | −0.16 | ||
| −0.19 | 0.03 | −0.30 | 0.11 | ||
a Positive control: 50 nM of tariquidar (109.59% inhibition), negative control: 2% DMSO (−0.42% inhibition).
Figure 3Chemo-sensitizing activity of compounds 1–10 on the two lymphoma cell lines. (A,B) Show the IC50 value of doxorubicin (Dox) alone or in combination with 10 or 25 μM of 20-hydroxyecdysone 2,3;20,22-diacetonide (20DA) or compounds 1–10. The dashed line marks the threshold of two-fold sensitization. With the exception of 10 μM of compound 1 (either cell line), and 2, 3, and 9 (L5178), all IC50 values differ from that found for Dox alone at p < 0.01 by means of one-way ANOVA followed by Dunnett’s post-hoc test; IC50 values and levels of significance are provided as supporting information (Table S1); (C) Fold sensitization on both cell lines is presented, corresponding to how many times a certain concentration (10 or 25 μM) of the tested compound decreased the IC50 of Dox as compared to when it was used alone; MDR selectivity refers to the ratios of the IC50 values on the resistant and sensitive cell line: MDR selectivity = IC50(L5178MDR)/IC50(L5178).